Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global Overactive Bladder Treatmentmarket was valued at USD 3.44billion in 2016 and is projected to reach USD 4.43billionby 2025, growing at a CAGR of 2.84% from 2017 to 2025.
An overactive bladder causes a sudden urge to urinate. It can also trigger involuntary loss of urine, known as incontinence. Overactive bladder affects mostly women and geriatric population. The health issue is highly prevalent and the market is expected to grow during the forecast period.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Improved innovations in Intravesical therapies
1.2 High level marketing by pharma companies
1.3 Increase geriatric population
1.4 Rising number of cases of Diseases Characterized By OAB
2. Market Restraints
2.1 Undesired Systemic Effects of Current OAB Treatments
Market Segmentation:
1. By Disease:
1.1 Idiopathic Overactive Bladder
1.2 Neurogenic Overactive Bladder
1.2.1 Overactive Bladder in Parkinson's Disease
1.2.2 Overactive Bladder in Stroke
1.2.3 Overactive Bladder in Multiple Sclerosis
1.2.4 Overactive Bladder in Spinal Cord Injury
1.2.5 Overactive Bladder in Other Disorders
2. By Pharmacotherapy:
2.1 Anticholinergics
2.1.1 Solifenacin
2.1.2 Oxybutynin
2.1.3 Fesoterodine
2.1.4 Darifenacin
2.1.5 Tolterodine
2.1.6 Trospium
2.1.7 Other Anticholinergics
2.2 Mirabegron
2.3 Botox
2.4 Neurostimulation
2.5 Intravesical Instillation
3. By Region:
3.1 North America (U.S., Canada, Mexico)
3.2 Europe (Germany, UK, France, Rest of Europe)
3.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
3.4 Latin America (Brazil, Argentina, Rest of Latin America)
3.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Astellas Pharma Inc.
2. Pfizer, Inc.
3. Teva Pharmaceutical Industries Limited
4. Allergan, PLC.
5. Mylan N.V.
6. Endo International PLC
7. Hisamitsu Pharmaceutical Co., Inc.
8. Sanofi
9. Aurobindo Pharma Limited
10. Johnson & Johnson
11. Intas Pharmaceuticals Ltd.
12. Apotex Inc.
13. Macleods Pharmaceuticals Ltd.
14. Medtronic PLC
15. Cogentix Medical, Inc.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Overactive Bladder Treatmentmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
Request Sample 
Request Discount 
Inquire Before Buy
